Table 3. Median overall survival durations in subgroups based on combined hENT1 and DPD tumour expression status. Treatment Subgroup Number of Median P value P value post Arm patients overall survival (raw) Bonferroni (95% CI) correction months 5-fluorouracil 9 17.3 with folinic acid DPD-high (0.6-38.0) 0.81 1.000 hENT1-high 39 26.0 DPD-low (19.8-30.1) hENT1-low 17 9.7 DPD-high (5.3-30.4) 0.002 0.014 47 29.2 hENT1-low DPD-low (19.5-41.9) Gemcitabine 12 22.3 DPD-high (9.6-39.5) 0.060 0.360 hENT1-high 57 26.3 DPD-low (17.2-33.0) hENT1-low 11 14.0 DPD-high (9.1-15.7) 0.730 1.000 hENT1-low 38 18.0 DPD-low (7.6-15.3) FIGURES Kaplan-Meier survival curves and median overall survival for DPD-low vs. Figure 1. DPD-high tumour expression in the entire chemotherapy treated population (5FU/FA plus gemcitabine), 5FU/FA treated patients, gemcitabine treated patients, and the small observational (OBS) population.
Table 3. Median overall survival durations in subgroups based on combined hENT1 and DPD tumour expression status. Treatment Arm Subgroup Number of patients Median overall survival (95% CI) months P value (raw) P value post Bonferroni correction 5-fluorouracil with folinic acid DPD-high 9 17.3 (0.6-38.0) 0.81 1.000 hENT1-high DPD-low 39 26.0 (19.8-30.1) hENT1-low DPD-high 17 9.7 (5.3-30.4) 0.002 0.014 hENT1-low DPD-low 47 29.2 (19.5-41.9) Gemcitabine DPD-high 12 22.3 (9.6-39.5) 0.060 0.360 hENT1-high DPD-low 57 26.3 (17.2-33.0) hENT1-low DPD-high 11 14.0 (9.1-15.7) 0.730 1.000 hENT1-low DPD-low 38 18.0 (7.6-15.3) FIGURES Figure 1. Kaplan-Meier survival curves and median overall survival for DPD-low vs. DPD-high tumour expression in the entire chemotherapy treated population (5FU/FA plus gemcitabine), 5FU/FA treated patients, gemcitabine treated patients, and the small observational (OBS) population.